Home > Boards > US OTC > Delisted >

Spotlight Innovation Inc. (fka STLT)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 7/1/2021 9:31:48 AM - Followers: 31 - Board type: Free - Posts Today: 0


Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies
which have unique intellectual property (IP) in the medical sector.
The Company utilizes relationships with the nation’s leading academic and institutional IP developers to
locate promising IP technologies with potential for market share capture.
With their support, development, resources and strategic planning expertise, Spotlight Innovation believes
they can develop IP that will have a positive effect on healthcare.
They intend to partner with proven sector leaders on commercialization once technologies are fully developed.

Verified Company Profile3/29/2016
Contact Info
  • 6750 Western Parkway
    Suite 200-226
    West Des Moines, IA 50266
TLT Security Details
Share Structure
  Market Value1 $9,355,615 a/o Aug 29, 2016
  Authorized Shares 4,000,000,000 a/o Nov 04, 2014
  Outstanding Shares 15,856,974 a/o Aug 02, 2016
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 2,342,931 a/o Aug 02, 2016
  Par Value 0.001
Transfer Agent(s)
VStock Transfer LLC
Shareholders of Record 77 a/o Aug 02, 2016
Security Notes
  • Capital Change=shs increased by 14 for 1 split. Payable upon surrender. Pay date=08/19/2008.
    Capital Change=Stk. Div.=50% Ex-date=04/15/2009. Rec date=03/26/2009. Pay date=04/14/2009.
    Capital Change=shs decreased by 1 for 500 split. Ex-date=12/19/2013.

ZACKs Analyst report issued August 2015 http://share.myflare.com/MqVG9g


Website: http://www.spotlightinnovation.com

LinkedIn Company Page: http://www.linkedin.com/company/spotlight-innovation

YouTube/Google+ Company: http://www.youtube.com/user/spotlightinnovation

Twitter: https://twitter.com/SpotlightInno

Facebook: https://www.facebook.com/SpotlightInnovation


6750 Westown Pkwy, Suite 200-226
West Des Moines, IA 50266
Phone: 515-274-9087



Spotlight Innovation subsidiary 
Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office

Spotlight Innovation signs 
Memorandum of Understanding (MOU) with Black Swan LLC


Spotlight Innovation signs 
Letter of Intent to Acquire Memcine Pharmaceuticals

Spotlight Innovation 
retains Jerry Cirino as Special Advisor

Spotlight Innovation 
retains Barwicki Investor Relations

Spotlight Innovation
 publishes White Paper “Midwest Universities are Cultivating IP Commercialization Success”

JULY 2014
Spotlight Innovation receives 
$250,000 Line of Credit from Denver Savings Bank

JUNE 2014
Spotlight Innovation
 hires Dr. Hostelley as CFO

JUNE 2014
Spotlight Innovation closes 
equity placement of more than $41M: released to Company under certain specified conditions

JUNE 2014
Share exchange agreement finalized between Celtic Biotech Iowa and Celtic Biotech LTD, completing Celtic Biotech LTD acquisition

APRIL 2014
Spotlight Innovation
 receives $752,325 Line of Credit from Denver Savings Bank, secured by Jared DeVries

MARCH 2014
Celtic Biotech Iowa, Inc., becomes wholly-owned subsidiary of Spotlight Innovation Inc.


AEXP/Spotlight Innovation merger completed


March 10, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa licenses promising therapy for Chronic Kidney Disease

Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD).
Read more…

January 15, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office

Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief.  The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Read more…

January 6, 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC

Spotlight Innovation Inc. (OTCQB:STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Read more…

December 16, 2014
Spotlight Innovation announces change of Transfer Agent

Spotlight Innovation Inc. (OTCQB:STLT) announces today that effective December 16, 2014, all communications related to shareholder transactions should be directed to VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
Read more…

December 4, 2014
Celtic Biotech Iowa requests reactivation and transfer of National Drug Code registration

Spotlight Innovation Inc. (OTCQB:STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product.
Read more…

October 14, 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals

Spotlight Innovation Inc. (OTCQB:STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex™ vaccine platform technology, which is designed to use the body’s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Read more…

October 1, 2014
Spotlight Innovation Retains Jerry Cirino as Special Advisor

Spotlight Innovation Inc. (OTCQB: STLT) has hired Jerry Cirino as a Special Advisor to provide business development expertise and to advise the Company on strategic opportunities and transactions.
Read more…

September 24, 2014
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program

Spotlight Innovation, Inc. (OTCQB: STLT) announced that it has retained Barwicki Investor Relations, a New York-based investor relations firm, to expand the Company’s strategic investor relations program. Barwicki Investor Relations is providing financial community and media relations, and editorial, consulting and advisory services.
Read more…

August 27, 2014
Spotlight Innovation white paper focuses on evolution of efforts to transform University research into profitable business ventures

Spotlight Innovation, Inc. (OTCQB:STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP).
Read more…

August 5, 2014
Spotlight Innovation signs second Letter of Credit with Denver Savings Bank

Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Read more…

July 02, 2014
Spotlight Innovation, Inc., announces closing of financing

Spotlight Innovation, Inc., (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors, through its equity advisor Catwalk Capital, LLC.
Read more…

June 26, 2014
Spotlight Innovation names Dr. David Hostelley Chief Financial Officer

Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company.
Read more…

June 17, 2014
Spotlight Innovation building relationships with Midwest businesses and people

Cristopher Grunewald, President and CEO of Spotlight Innovation said, “The Midwest is a hotbed of talent and innovation, and it has always been a pillar of our business plan to build relationships with people and institutions in the Midwest. We are pleased that we are making good on this commitment.”
Read more…

June 10, 2014
Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., completes merger with Celtic Biotech Ltd.

Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 4, 2014, Celtic Biotech Iowa, Inc. (a subsidiary of Spotlight Innovation, Inc.) has completed a share exchange agreement with biopharmaceutical company Celtic Biotech Ltd.
Read more…

December, 16, 2013
Spotlight Innovation’s name change, symbol change and reverse split approved by FINRA

Spotlight Innovation, Inc. (“the Company”) (OTCQB:STLT) is pleased to announce that effective December 17, 2013 the Financial Industry Regulatory Authority (“FINRA”) has approved the name change of the company from American Exploration Corp. to Spotlight Innovation, Inc., change of stock symbol to “STLT”, and a 1-500 reverse split of our common stock.
Read more…

December 12, 2013
Spotlight Innovation, Inc. Announces Name Change and Closing of Merger

Spotlight Innovation, Inc. (formerly American Exploration Corporation, AEXP:OTCQB), announced today the completion of a merger with Spotlight Innovation, LLC.
Read more…

Spotlight Innovation is committed to developing quality-of-life-enhancing biotechnologies that have the potential to positively impact the health, well-being and longevity of an enormous number of lives. We are building a portfolio of healthcare/life sciences subsidiary companies, each having the potential to further our commitment.

Celtic Biotech Iowa Inc.

Celtic Biotech, Inc.

Celtic Biotech Iowa Inc., is developing novel therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.

Celtic Biotech Iowa Inc. is a subsidiary of Spotlight Innovation Inc.

Read the press release here.

Additional information about Celtic Biotech here.

Celtic Biotech Iowa Inc.



Cristopher Grunewald, CEO

Mr. Grunewald is a financial executive and entrepreneur with background in the healthcare and biotechnology sectors, private equity and investment banking. He has been involved in all stages of the commercialization of healthcare IP developed by premiere research and development institutions.

Dr. David Hostelley, CFO

Dr. Hostelley has twenty years as a consultant in the health field, and has served as CEO, CFO and board member of several publicly traded companies. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio.

Jeffrey Stein, Esq., Securities Counsel

Mr. Stein serves as securities counsel for Spotlight Innovation. He has over fifteen years of experience providing high quality, personalized attention to public companies, including more than thirty reverse mergers, IPOs and APOs.

Rene Erickson, Corporate Communications

Mr. Erickson has three decades of corporate communications experience across diverse industries including healthcare, information technology, aviation and academia.

Mike Reysack, Investor Relations

Mr. Reysack leads Investor Relations for Spotlight Innovation. He has extensive experience cultivating and managing relationships with financial stakeholders, including fifteen years as an Investor Relations consultant and business strategist for venture and early stage companies, providing effective communications between companies and the financial community.

Special Advisor

Jerry Cirino

Mr. Cirino is a healthcare technology executive with extensive background in medical devices, distribution and healthcare information in private equity and public environments. His experience includes management of complex growth and transition environments including M&A, integrations and global operations, and he is a proven consultant in transaction evaluation, due diligence and strategic planning.

Partner Firms


GBH CPAs, PC, Houston, TX

Transfer Agent

VStock Transfer, LLC, Woodmere, NY

Law Firms

Davis Brown Law Firm, Des Moines, IA
JMS Law Group, New York, NY
Eilers Law Group, Miami, FL
Whitfield & Eddy, P.L.C., Des Moines, IA


#2020   STLT registration revoked: Renee 07/01/21 09:31:48 AM
#2019   STLT is current in Nevada, SOS, has a Ecomike 04/10/21 10:57:10 PM
#2018   Here is the text of the Proxy, that Ecomike 03/31/21 07:00:33 PM
#2017   Looks like the Nevada SOS data on STLT Ecomike 03/31/21 06:53:37 PM
#2016   I did some checking and found the broker Ecomike 03/31/21 04:57:05 PM
#2015   Interesting update, thanks. Ecomike 03/30/21 02:02:36 PM
#2014   https://www.sec.gov/litigation/opinions/2021/34-91440.pdf lucky,mydog 03/30/21 01:46:29 PM
#2013   So what is the score here with STLT Ecomike 12/29/20 12:35:03 PM
#2012   You seeing this? Ecomike 10/21/20 06:19:34 PM
#2011   Got a court case number, and link, which Ecomike 10/12/20 11:10:20 AM
#2010   Find PRINCIPAL SECURITIES, INC., Petitioner, vs. SANJEEV AspenLake 10/10/20 05:33:29 PM
#2009   Yes, this is one of the oddest ones Ecomike 07/14/20 10:33:14 AM
#2008   sorry for your loss my man, same for PennyStockTrader2 07/14/20 10:03:40 AM
#2007   I invested in STLT when it was a Ecomike 07/10/20 12:53:22 AM
#2006   By the way, regulations are not laws. SEC janice shell 07/09/20 11:05:08 PM
#2005   LOL, I have yet to find a company Ecomike 07/09/20 10:43:51 PM
#2004   I assume you knew STLT was two years' janice shell 07/09/20 10:09:49 PM
#2003   Yes, but I am the one that got Ecomike 07/09/20 09:55:44 PM
#2002   This is entirely the fault of STLT. janice shell 07/09/20 03:14:02 PM
#2001   Note worthy that the 2 CEOs, Directors of Ecomike 07/09/20 11:39:39 AM
#2000   Looking around Ebay I see a whole lot Ecomike 07/09/20 11:27:09 AM
#1999   Well that is a shame. They actually had Ecomike 07/09/20 10:58:07 AM
#1998   STLT SEC Suspension for severely delinquent Financials: Renee 07/09/20 09:39:01 AM
#1997   suspended. lucky,mydog 07/09/20 09:37:28 AM
#1996   The stock is too cheap for a 9 Ecomike 05/20/20 01:49:39 AM
#1995   no I ended up selling to take a PennyStockTrader2 05/19/20 05:16:02 PM
#1994   Since I have seen no volume selling for Ecomike 05/19/20 04:00:08 PM
#1993   Signs of life on the ticker here. $500 Ecomike 05/19/20 01:11:22 PM
#1992   Found some more recent news on STLT Biotech Ecomike 06/28/19 01:09:26 PM
#1991   More signs of life here day 2, and Ecomike 05/29/19 10:27:14 AM
#1990   $STLT heads up, No one spends $1200 buying Ecomike 05/15/19 01:59:45 PM
#1989   No one spends $1200 buying a dead stock Ecomike 05/15/19 12:42:23 PM
#1988   A large ask slap at a 50% premium Ecomike 05/15/19 10:59:35 AM
#1987   An ask slap :-) Ecomike 03/27/19 11:11:18 AM
#1986   Phone and website work, but no one answers Ecomike 03/06/19 02:06:47 PM
#1985   Interesting rise going on here. Ecomike 02/07/19 02:57:59 PM
#1984   I was wondering whose bid that was. Ecomike 02/05/19 12:02:11 PM
#1983   Was doing some DD here today. Tried to Ecomike 02/05/19 11:49:20 AM
#1982   yes I am on that same mailer and PennyStockTrader2 01/08/19 12:54:22 PM
#1981   I got an email update from the STLT Ecomike 01/08/19 11:53:21 AM
#1980   $100 in trade volume? junkHustler 12/27/18 05:02:45 PM
#1979   Make what stuff up? It is up 467% Ecomike 12/27/18 03:02:05 PM
#1978   .OOPs LOL How long can it go? junkHustler 12/26/18 05:23:05 PM
#1977   The Bulls are back now, bid up 150% Ecomike 12/26/18 02:56:32 PM
#1976   Bids already at .0050 now. I am also Ecomike 12/26/18 02:52:24 PM
#1975   Im bidding 400K shares @.004 to see what PennyStockTrader2 12/26/18 01:47:37 PM
#1974   The bears are back, down 70% or 95% Ecomike 12/26/18 01:11:25 PM
#1973   Convertible debt fear is one issue, they have Ecomike 12/24/18 11:07:47 AM
#1972   A couple things, while the rub may work PennyStockTrader2 12/24/18 12:54:26 AM
#1971   Two years ago the 10-K was delayed and Ecomike 12/24/18 12:05:45 AM
Consent Preferences